The knockdown of FBP1 not only increased the pancreatic cancer cells viability (Fig. 1c and f), but also promoted PANC-1 cell resistant to JQ1 drug via decreasing the cleaved PARP expression and caspase-3 activity (Fig. 1c-1f). This evidence concerns the gene CASP3 and familial pancreatic carcinoma.